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Summary
 
Although most leukocytes, T lymphocytes in particular, respond to several different chemo-
kines, there is virtually no information on chemokine activities and chemokine receptors in B
lymphocytes. A putative chemokine receptor, BLR1, that is expressed in Burkitt’s lymphoma
cells and B lymphocytes was cloned a few years ago. Deletion of the gene for BLR1 yielded
mice with abnormal primary follicles and germinal centers of the spleen and Peyer’s patches,
reflecting the inability of B lymphocytes to migrate into B cell areas. By screening expressed se-
quence tag DNA sequences, we have identified a CXC chemokine, termed B cell–attracting
chemokine 1 (BCA-1), that is chemotactic for human B lymphocytes. BCA-1 cDNA encodes
a protein of 109 amino acids with a leader sequence of 22 residues. The mature protein shares
23–34% identical amino acids with known CXC chemokines and is constitutively expressed in
secondary lymphoid organs. BCA-1 was chemically synthesized and tested for activity on mu-
rine pre–B cells 300-19 transfected with BLR1 and on human blood B lymphocytes. In trans-
fected cells, BCA-1 induced chemotaxis and Ca
 
2
 
1
 
 mobilization demonstrating that it acts via
BLR1. Under the same conditions, no activity was obtained with 10 CXC and 19 CC
chemokines, lymphotactin, neurotactin/fractalkine and several other peptide ligands. BCA-1
was also a highly effective attractant for human blood B lymphocytes (which express BLR1),
but was inactive on freshly isolated or IL-2–stimulated T lymphocytes, monocytes, and neutro-
phils. In agreement with the nomenclature rules for chemokine receptors, we propose the term
CXCR5 for BLR1. Together with the observed disturbance of B cell colonization in BLR1/
CXCR5-deficient mice, the present results indicate that chemotactic recruitment by locally
produced BCA-1 is important for the development of B cell areas of secondary lymphoid tis-
sues.
 
I
 
n the past few years, major progress has been made in the
understanding of the role of chemokines in T lympho-
cyte recruitment (1). T cells respond to CXC and CC
chemokines and express many different chemokine receptors,
some of which are upregulated by IL-2 (2). Of particular in-
terest is a new group of CC chemokines that were identi-
fied recently, such as TARC (3), ELC/MIP-3
 
b
 
 (4, 5),
LARC/MIP-3
 
a
 
/exodus (5–7), and SLC (8), which are ex-
pressed preferentially in lymphoid tissues and are chemo-
tactic for T lymphocytes. Another CC chemokine, DC-CK1/
PARC (9, 10) is expressed by dendritic cells of germinal
centers and was reported to attract naive T lymphocytes
(9), suggesting a role for the onset of immune reactions.
There is little information, however, on chemokine ac-
tivities and chemokine receptor expression on B lympho-
cytes. Two newly identified CC chemokine receptors,
CCR6 (11) and CCR7 (4), were reported to be present in
T and B cells, but no ligand was found that induces
chemotaxis of B lymphocytes. SDF-1, a CXC chemokine
that was originally described as a growth factor for progen-
itor B cells, is chemotactic for human pre– and pro–B cell
lines, but does not attract mature B lymphocytes (12). The
search for chemokines that attract B cells was stimulated by
the cloning of a receptor termed BLR1 (13) or MDR15
(14) that is highly expressed in Burkitt’s lymphoma cells
and B lymphocytes and has considerable structural similar-
ity to known chemokine receptors. Deletion of the gene
for BLR1 in mice (15) yielded a remarkable phenotype.
The 
 
2
 
/
 
2
 
 animals lack inguinal lymph nodes and have a
defective formation of primary follicles and germinal cen-
ters of the spleen and of Peyer’s patches. Receptor-defi-
cient B lymphocytes enter T cell areas, but do not migrate
  
656
 
B Cell–attracting Chemokine 1 (BCA-1) Acts via BLR1
 
into B cell areas suggesting that the BLR1 ligand is essential
for the homing of B lymphocytes and the proper develop-
ment of B cell–rich regions of lymphoid tissues.
To search for the ligand of BLR1/MDR15, we screened
the expressed sequence tag (EST) data bank for CXC
chemokine motifs and cloned a yet uncharacterized CXC
chemokine termed B cell–attracting chemokine (BCA)-1,
which attracts cells transfected with BLR1. The present pa-
per shows that BCA-1 is expressed in lymphoid tissues and
is a selective and highly efficacious chemoattractant for hu-
man blood B lymphocytes.
 
Materials and Methods
 
Agonists.
 
BCA-1, reference chemokines, and neuropeptide Y
(NPY) were chemically synthesized according to established pro-
tocols (16). The novel chemokines I-TAC and HCC-2 were
supplied by Dr. K. Neote (Pfizer Central Research, Groton, CT)
and Dr. W.G. Forssmann (Lower Saxony Institute for Peptide Re-
search (IPF), Hannover, Germany). C5a and C3a were provided
by Dr. C.A. Dahinden (University Hospital, Bern, Switzerland).
Somatostatin, substance P, and calcitonin were purchased from
Sigma Chemical Co. (St. Louis, MO).
 
Cells.
 
Human neutrophils (17), monocytes (18), and PBLs
were isolated from donor blood buffy coats, and PBLs were acti-
vated by culturing with IL-2 (2). B lymphocytes were isolated
from blood mononuclear cells by positive selection with a mouse
anti–human CD20 mAb (Immunotech, Marseille, France) and
MACS goat anti–mouse IgG microbeads (19) after depletion of
monocytes by adherence to plastic. Purity was assessed by FACS
 
Ò
 
analysis (mouse anti–human CD19, Sigma Chemical Co.; mouse
anti–human CD3, Becton Dickinson, Mountain View, CA). Be-
fore use in chemotaxis and Ca
 
2
 
1
 
 mobilization assays, B lympho-
cytes were incubated for 30 min at 37
 
8
 
C.
 
Cloning of BCA-1.
 
The coding sequence of BCA-1 was gen-
erated by PCR using human spleen cDNA as template and the
primers BCA-1SE, 5
 
9
 
-GGGCTGCAGCTCCAGACAGAAT-
GAAGTTC, containing the start codon, and BCA-1AS, 5
 
9
 
-GGA-
CTCGAGTGGAAATATCAGCATCAGGG, including the stop
codon. PCR amplification was performed in volumes of 30 
 
m
 
l,
containing 1
 
3
 
 PCR buffer including 1.5 mM MgCl
 
2
 
 (GIBCO
BRL, Paisley, UK), 0.4 
 
m
 
M primers, 280 
 
m
 
M dNTPs, and 2 
 
m
 
l
of cDNA preparation. To start DNA synthesis, 1.5 U Taq-poly-
merase (GIBCO BRL) was added after cDNA denaturation and
allowed to progress for 30 cycles (1 min at 57
 
8
 
C, 45 s at 72
 
8
 
C, 15 s
at 95
 
8
 
C) in a master cycler (5330; Eppendorf-Netheler-Hinz,
Hamburg, Germany). The amplified DNA was purified, digested
with PstI and XhoI, subcloned into the vector pBluescript SK
(Stratagene Corp., La Jolla, CA), and three independent clones
were sequenced to completion.
 
BLR1 Transfectants.
 
BLR1 DNA was generated by PCR
with cDNA from freshly isolated PBLs as template and the prim-
ers BLR1SE, 5
 
9
 
-TTAGAATTCGACTCACAGCCGGCACAGC,
and BLR1AS, 5
 
9
 
-GTGAGCCCTTAGGATCCCAGC, corre-
sponding to positions 65–83 and 1,276–1,296 of the published se-
quence of BLR1 (13), spanning the entire coding region of 372
amino acids. PCR amplification was performed as described (20).
The amplified DNA was purified, digested with EcoRI and BamHI,
subcloned into the mammalian expression vector SR
 
a
 
puro (pro-
vided by Dr. F. Arenzana-Seisdedos, Pasteur Institute, Paris,
France), and sequenced. Stable transfectants were generated with
20 
 
m
 
g of linearized SR
 
a
 
puro-BLR1 plasmid DNA in murine
pre–B cells 300–19 (5 
 
3
 
 10
 
6
 
 cells in 400 
 
m
 
l RPMI 1640; refer-
ence 21). Clones were established by limiting dilution in the
presence of 1.5 
 
m
 
g/ml puromycin (Sigma Chemical Co.) and
screened for BLR1 expression by RNA dot blot analysis.
 
Ca
 
2
 
1
 
 Responses to Chemokines.
 
Changes in the cytosolic free
intracellular Ca
 
2
 
1
 
 concentration ([Ca
 
2
 
1
 
]
 
i
 
) were measured in cells
loaded with fura-2 by incubation for 25 min at 37
 
8
 
C with 0.1
nmol fura-2/AM per 10
 
6
 
 cells in a buffer containing 136 mM
NaCl, 4.8 mM KCl, 1 mM CaCl
 
2
 
, 5 mM glucose, and 20 mM
Hepes, pH 7.4. After centrifugation, loaded cells were resus-
pended in the same buffer (2 
 
3
 
 10
 
6
 
 cells in 800 
 
m
 
l), stimulated
with the indicated chemokine at 37
 
8
 
C, and the [Ca
 
2
 
1
 
]
 
i
 
-related
fluorescence changes were recorded (22).
 
In Vitro Chemotaxis.
 
Cell migration was assessed in triplicate
in 48-well chambers as described by Loetscher et al. (23). RPMI
1640 supplemented with 20 mM Hepes, pH 7.4, and 1% pasteur-
ized human plasma protein solution (Swiss Red Cross Laboratory,
Bern, Switzerland) was used to dissolve the chemokines and to
suspend the cells. The duration of the assay was 120 min for
BLR1 transfectants, parental 300-19 cells, and B lymphocytes; 60
min for T lymphocytes; and 25 min for neutrophils and mono-
cytes. Migrating cells were stained on the lower side of the filters
and counted at 
 
3
 
1,000 magnification in five randomly selected
fields.
Expression was measured by Northern and dot blot analysis us-
ing a human RNA Master Blot
 
TM
 
 and a human Immune System
Multiple Tissue Blot II
 
TM
 
 (Clontech, Palo Alto, CA) as described
(2, 23). A 
 
32
 
P-labeled complete BCA-1 DNA (2 
 
3
 
 10
 
9
 
 cpm/
 
m
 
g)
was used as hybridization probe at 5 
 
3
 
 10
 
6
 
 cpm/ml hybridization
solution.
 
Results and Discussion
 
BCA-1 DNA and Protein.
 
A partial sequence of a puta-
tive human CXC chemokine was recently derived from
the EST DNA sequence T39765 (24). Using T39765 as
probe we searched the EST cDNA databank and identified
two additional sequences, AA298459 and T55152, provid-
ing the missing 5
 
9
 
- and 3
 
9
 
-sequence information. The re-
sulting DNA of 663 nucleotides has a putative open read-
ing frame of 327 nucleotides preceded by a stretch with
high similarity to the consensus of translation initiation se-
quences of vertebrates (25). DNA containing the whole
coding region of BCA-1 was generated by PCR using spleen
cDNA and specific oligonucleotide primers. Three inde-
pendent clones were sequenced to completion and found
to be identical. They differ from the EST-derived sequence
at position 47–48 (GC instead of CG) yielding a threonine
instead of a serine at position 16. The translated cDNA
consists of 109 amino acids (Fig. 1 
 
a
 
) and contains a hydro-
phobic sequence followed by a putative cleavage site be-
tween residues 22 and 23. The predicted secreted form of
87 residues was chemically synthesized and shown to acti-
vate cells expressing BLR1, indicating that it is a functional
form of the chemokine. In view of the biological activities
described below the chemokine was termed BCA-1. The
four cysteines of BCA-1 align with those of CXC chemo-
kines. In addition BCA-1 has an arginine residue immedi-
ately preceding the first cysteine, a feature that is conserved
in all CXC chemokines except platelet factor 4. Overall, it 
657
 
Legler et al. Brief Definitive Report
 
shares 24–34% sequence identity with CXC chemokines.
However, evolutionary distance comparison indicates that
BCA-1 is not closely related to any particular group of
chemokines. Like SDF-1, it appears to be segregated within
the CXC chemokine subfamily (Fig. 1 
 
b
 
).
Expression of BCA-1 was assessed with a DNA hybrid-
ization probe of 355 bp spanning the entire coding region.
In a dot blot analysis of 50 human tissue RNAs (Fig. 2 
 
a
 
),
the highest expression was found in the liver followed by
the spleen, lymph nodes, appendix, and stomach. Some ex-
pression was also detected in the salivary and mammary
glands, whereas all other tissues tested were negative. Sur-
vey of a number of fetal tissues yielded some expression in
the spleen only (data not shown). A Northern blot with a
Figure 1. (a) Nucleotide and deduced amino acid sequences of BCA-1.
Numbering starts at the first nucleotide of the start codon. The predicted
open reading frame is indicated below the nucleotide sequence, and the
putative signal peptide cleavage site is marked by an arrowhead. These se-
quence data are available from EMBL/Genbank/DDBJ under accession
number AJ002211. (b) Phylogenetic tree diagram of human CXC chemo-
kines. Similarity scores of the proteins were determined by average link-
age cluster analysis (33). Gap penalty, window size, filtration level, and
K-tulpe size parameters for pairwise alignments were set at 3, 10, 2.5, and
1, respectively. Distance to the branching points indicates percent se-
quence divergence.
Figure 2. Expression of BCA-1 in human tissues. (a) Dot blot analysis
using a DNA probe spanning the whole open reading frame of BCA-1.
The strongest signal, obtained with liver RNA (140,575 cpm), was taken
as 100%, and the relative expression in other tissues was calculated. The
lowest significant signal (2,759 cpm) was detected in the mammary gland.
Most tissues yielded counts around background (z50 cpm). Tissue sam-
ples that did not express BCA-1 transcripts included total brain, amygdala,
caudate nucleus, cerebellum, cerebral cortex, frontal lobe, hippocampus,
medulla oblongata, occipital lobe, putamen, substantia nigra, temporal lobe,
thalamus, subthalamic nucleus, spinal cord, heart, aorta, skeletal muscle,
colon, bladder, uterus, prostate, testis, ovary, pancreas, pituitary gland, ad-
renal gland, thyroid gland, kidney, small intestine, thymus, blood leuko-
cytes, bone marrow, lung, trachea, placenta, fetal brain, fetal heart, fetal
kidney, fetal liver, fetal thymus, and fetal lung. (b) Northern blot of hu-
man tissue RNAs hybridized with the same DNA probe.
Figure 3. BCA-1 responses
of murine pre–B cells 300-19
stably transfected with BLR1/
CXCR5. (a) Chemotaxis of pa-
rental (open circles) and BLR1/
CXCR5-expressing cells (closed
circles). Migrated cells (mean
counts  6 SD of triplicate assays
per five high power fields) from
one experiment that is represen-
tative of a total of six. (b) [Ca21]i
changes in BLR1/CXCR5-
expressing 300-19 cells. BCA-1
was added at 0.1, 1, 10, and 100
nM to fura-2–loaded cells (arrow-
heads), and [Ca21]i-dependent
fluorescence changes were re-
corded. Parental 300-19 cells
(control) were stimulated with
100 nM BCA-1. One out of five
independent experiments with
identical results is shown. 
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selection of lymphoid and myeloid RNAs showed high
levels of a single transcript of 1.4 kb in spleen and lymph
nodes, but not in the thymus, bone marrow, and blood
lymphocytes (Fig. 2 
 
b
 
). Since the RNA for dot and North-
ern blot analysis was obtained from normal tissues, BCA-1
expression in lymphoid tissues appears to be constitutive.
 
BCA-1 Is the Ligand for BLR1.
 
An elegant study by
Förster et al. (15) showed that disruption of the BLR1 gene
 
Table 1.
 
Chemokines and Other Protein Agonists Tested for 
Activity on Cells Expressing BLR1/CXCR5
 
*
 
CXC
chemokines
CC
chemokines
Other
chemokines
Other
peptides
BCA-1 RANTES Lymphotactin C3a
IL-8 MCP-1 Neurotactin C5a
GRO
 
a
 
MCP-2 Calcitonin
NAP-2 MCP-3 NPY
GCP-2 MCP-4 Somatostatin
ENA78 Eotaxin Substance P
Mig Eotaxin-2
IP10 MIP-1
 
a
 
I-TAC MIP-1
 
b
 
SDF-1 I-309
PF4 HCC-1
HCC-2
TARC
LARC
DC-CK1
CK
 
b
 
8
ELC
SLC
MDC
 
*
 
[Ca
 
2
 
1
 
]
 
i
 
 changes were determined in stably transfected 300-19 cells af-
ter stimulation with 100 nM agonist.
Figure 4. Functional re-
sponses of human blood leuko-
cytes to BCA-1. (a) In vitro
chemotaxis of human B lympho-
cytes (closed circles), T lympho-
cytes cultured for 19 d in the
presence of 250 U/ml IL-2 (open
circles), monocytes (open squares),
and neutrophils (open triangles) in
response to increasing concentra-
tions of BCA-1. (b) [Ca21]i
changes in human blood leuko-
cytes. Fura-2–loaded cells were
stimulated sequentially with 100
nM BCA-1 followed by another
chemokine, and changes in
[Ca21]i were recorded. The data
are representative for four inde-
pendent experiments.
in mice results in a defective formation of primary follicles
and germinal centers of the spleen and of Peyer’s patches
and the lack of inguinal lymph nodes. Receptor-deficient
B lymphocytes enter the T cell areas, but fail to migrate
into the areas that are normally populated by B cells. These
observations suggested that chemokines generated in hom-
ing tissues could direct the influx and the retention of
BLR1-bearing B cells. Since BCA-1 is highly expressed in
secondary lymphoid tissues, it was considered a promising
candidate ligand for BLR1. Synthetic BCA-1 was first
tested on clones of the murine pre–B cell line 300-19 stably
transfected with BLR1 DNA. This cell line has been suc-
cessfully used in our laboratory to express human chemo-
kine receptors and to assess chemokine-dependent functions
(20, 23). As shown in Fig. 3 a, BCA-1 induced chemotaxis
of BLR1-expressing cells with maximum migration at
100 nM, whereas the parental, nontransfected cells did not
respond. Furthermore a transient rise in [Ca21]i was elicited
by stimulation of BLR1 transfectants, but not of parental
300-19 cells (Fig. 3 b). A response was observed already at
1 nM BCA-1, and the rate and magnitude of the [Ca21]i
rise increased with the agonist concentration. 10 CXC and
19 CC chemokines, lymphotactin, neurotactin, as well as
several other peptide ligands (Table 1) were tested and
found to be inactive. These results demonstrate that the
CXC chemokine BCA-1 is the ligand for BLR1, and show
that no other known chemokine is recognized by this re-
ceptor. According to the current chemokine receptor no-
menclature, we propose the term CXCR5 for the orphan
receptor formerly known as BLR1.
BCA-1 Is Selective for B Lymphocytes. The chemotactic ac-
tivity of BCA-1 was then tested on B and T cells, mono-
cytes, and neutrophils. As shown in Fig. 4 a, B lymphocytes,
which express high levels of BLR1/CXCR5 (13), mi-
grated in a concentration-dependent manner in response to
BCA-1. The efficacy of BCA-1 was extraordinarly high, as
.60% of the input cells were recovered on the lower sur-
face of the filter or in the lower well at the highest agonist
concentration. The potency, however, was moderate since
concentrations of at least 100 nM were needed. The reason
for the superior efficacy but lower potency of BCA-1 in B659 Legler et al. Brief Definitive Report
lymphocytes as compared to BLR1-transfected 300-19 cells
is not clear at present. BCA-1 was not chemotactic for T
lymphocytes, monocytes, and neutrophils (Fig. 4 a). Con-
trols showed that these leukocytes migrated normally in re-
sponse to SDF-1, MCP-1, and IL-8, respectively (data not
shown). As shown in Fig. 4 b, BCA-1 did not induce
[Ca21]i changes in B lymphocytes, even at concentrations
as high as 1 mM. As expected, BCA-1 also did not induce
Ca21 mobilization in T lymphocytes, monocytes, and neu-
trophils, and did not prevent the effects of the chemokines
that induce chemotaxis in these cells (Fig. 4 b).
The pattern of biological activity of BCA-1 is somewhat
unusual. It is selective for B lymphocytes that are attracted
with high efficacy and relatively low potency. In terms of
efficacy, BCA-1 is similar to SDF-1, which was shown to
attract unexpectedly high numbers of T lymphocytes in
vitro (26). Another feature is its constitutive rather than in-
duced expression, and in this respect, BCA-1 is again simi-
lar to SDF-1 (27). BCA-1, is unique among chemokines in
its selectivity for B cells, whereas SDF-1 acts via a broadly
distributed receptor and attracts T lymphocytes, monocytes,
neutrophils, as well as B cell precursors (12, 26, 28, 29).
Despite its high chemotactic efficacy, BCA-1 did not in-
duce [Ca21]i changes in B cells. It is known from studies
with neutrophils that the shape change induced by chemo-
attractants, which is regarded as a correlate to cellular mo-
tion, does not require intracellular Ca21 mobilization (30).
The mechanism of signaling by chemoattractants in B cells
has not been studied, and experiments with BCA-1 may
uncover differences with respect to other leukocytes.
It has been recently recognized that certain chemokines are
involved in the regulation of lymphocyte homing rather
than in the recruitment of leukocytes into inflamed tissues.
It was suggested that DC-CK1/PARC, a chemokine that
is selectively expressed by dendritic cells of germinal cen-
ters, attracts naive T lymphocytes and may thus be involved
in the initiation of an immune response (9, 10). SDF-1 is
consitutively produced by stromal cells of the bone marrow
and was originally identified as a factor that stimulates the
growth of immature B cells (31). Since SDF-1 is chemotac-
tic for pro– and pre–B lymphocytes, it may act in lym-
phopoiesis by attracting these progenitors into close contact
with stromal cells where growth and differentiation factors
are released (12). It was also proposed that SDF-1 may di-
rect the homing of progenitor cells to their bone marrow
maturation sites (32), and may support bone marrow colo-
nization by hematopoietic precursor cells during embryo-
genesis (26). The finding that the ligand for BLR1 is a
chemokine provides further evidence for chemokine func-
tions that are not related to inflammation and immune pa-
thology. Together with the observed disturbance of B cell
colonization in BLR1/CXCR5-deficient mice (15), the
present results indicate that chemotactic recruitment by lo-
cally produced BCA-1 and possibly other B cell–attracting
chemokines is important for the development of B cell ar-
eas of secondary lymphoid tissues.
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